In life sciences, the stakes of a less-informed decision compound quickly. An acquisition that looks clean on paper can close with a manufacturing operation riddled with data integrity gaps. A partnership with a promising CDMO can unravel when a surprise Form 483 surfaces six months into tech transfer. A Venture Capital (VC), Private Equity (PE), or partner investment in a clinical-stage biotech can crater when commercial readiness turns out to be years - and tens of millions of dollars - further away than the data room suggested.
This is the terrain where QxP operates. And it's where technical due diligence, done right, becomes one of the highest-value investments in any transaction. QxP brings former executive operators who understand what will actually survive Regulatory Agency scrutiny post-close and what will collapse under commercial pressure.
What "Due Diligence" Actually Means in Pharma
Financial due diligence tells you what something is worth. Technical due diligence tells you whether that valuation holds up - or whether there's a remediation program quietly hiding behind the headlines.
In the pharmaceutical industry, a complete assessment spans product pipeline/novel technology/platform, manufacturing capabilities, regulatory history, quality systems, clinical data, intellectual property, and organizational readiness. Miss any one of these, and you're not just leaving money on the table. You're potentially acquiring someone else's enforcement action.
QxP's due diligence work is built on decades of hands-on experience across every dimension of pharmaceutical and biotech operations - from GxP quality systems and CMC development to aseptic manufacturing, advanced therapy medicinal products (ATMPs), and global regulatory filings. That depth and our comprehensive, integrated assessments are what enable our teams to get to every detail that could affect valuation - before it surfaces as a post-close surprise.
What QxP Evaluates
Technical and Scientific Readiness
Our technical experts assess the scientific validity and scalability of a target's pipeline with specific expertise in small molecules, biologics, biosimilars, ADCs, cell and gene therapies, including CAR-T, and ATMPs. We ask - and answer - the hard questions:
- Are analytical methods sufficiently developed, validated, and suitable for their intended purpose - from characterization through release and stability testing?
- Are manufacturing processes robust, validated, and transferable to a commercial or CDMO setting?
- Is the development program documented and genuinely ready for commercialization, or are there unresolved gaps that add years and cost to the timeline?
- Are there latent risks in process development, formulation, or stability programs that could delay approvals or trigger post-deal surprises?
- Are there latent risks in process development, formulation, or stability programs that could delay approvals or trigger post-deal surprises?
Regulatory and Compliance History
A target's regulatory history is one of the most information-dense datasets available - if you know how to read it. QxP digs into inspection records, filing histories (NDA, ANDA, BLA), and quality systems to identify patterns that predict future risk:
- Prior Form 483 observations and whether responses were truly resolved or papered over
- Warning letters, consent decrees, or import alerts and the systemic issues that drove them
- Alignment of quality systems with current ICH, FDA, and EMA expectations
- Data integrity across development and manufacturing records
- First-time inspection readiness - for organizations with no prior inspection history, we assess whether quality systems, documentation practices, and site readiness are genuinely prepared for regulatory scrutiny, or whether a first inspection represents a material undisclosed risk
What we're looking for isn't just historical problems - it's evidence of whether an organization has the culture and systems to prevent future ones.
Quality Systems and Operational Maturity
QxP evaluates the maturity of a target's Quality Management System (QMS) not just as a compliance artifact, but as a predictor of operational performance and inspection readiness. We assess:
- Overall Risk Framework
- Governance structures and decision-making velocity
- CDMO dependencies and the risks embedded in those relationships
- Supply chain redundancy and resilience
- SOP and training program robustness
A quality system that looks functional at a snapshot may be fragile under the pressure of scale, technology transfer, or post-acquisition integration.
IP and Technology Landscape
For platform technologies and proprietary formulations, QxP supports freedom-to-operate assessments, patent lifecycle analysis, and evaluation of genuine technology differentiation. We help acquirers understand not just what IP exists, but how defensible it is - and what it would cost to work around a blocking position if needed.
Organizational and Cultural Readiness
Culture is consistently underestimated in pharmaceutical transactions. Post-close, the quality culture of an acquired organization becomes your quality culture. QxP assesses organizational structure, leadership dynamics, and workforce readiness - not to produce soft insights, but to quantify the change management investment required for successful integration.
How QxP Serves Different Clients
For Pharma and Biotech Companies
Whether you're acquiring a clinical-stage asset, licensing a platform technology, or evaluating a partnership, QxP provides the technical depth that most M&A advisory teams cannot replicate in-house. We work as an integrated extension of your deal team -embedded in the data room process, translating scientific and regulatory complexity into risk-adjusted business language your decision-makers can act on.
We also prepare the other side of the table. If your organization is preparing for incoming due diligence from a potential acquirer or partner, QxP can identify gaps before they're surfaced by someone else - giving you time to remediate, contextualize, or simply not be surprised during negotiations.
For CDMOs
CDMOs face due diligence from two directions simultaneously: sponsors evaluating them as manufacturing partners, and investors or acquirers assessing them as investment targets.
QxP understands both perspectives. We've helped CDMOs demonstrate quality system maturity, prepare for sponsor audits, and navigate the regulatory complexity that comes with supporting advanced modality programs -cell and gene therapies, ADCs - where the stakes and the scrutiny are highest. We also help CDMOs present their capabilities compellingly and accurately when investor or acquirer due diligence begins.
On the sponsor side, we help biotech and pharma companies evaluate CDMO partners rigorously before committing manufacturing programs - assessing capacity, capability, regulatory track record, and the often-overlooked question of whether a CDMO's quality culture is compatible with the sponsor's risk tolerance.
For Private Equity and Venture Capital Investors
Financial investors in life sciences face a specific challenge: the technical risk is often the largest risk in the deal, but it requires domain expertise most investment teams don't carry internally.
QxP closes that gap. We translate manufacturing risk, regulatory exposure, and quality system maturity into the language of investment decisions - timeline risk, remediation cost, probability of regulatory delay, and enterprise value impact. We help investors price risk accurately, structure deals with appropriate protections, and build post-close value creation plans grounded in operational reality.
For portfolio companies, QxP serves as an ongoing resource - identifying emerging compliance risks before they become enforcement actions, implementing a risk framework, supporting prioritized, risk-based operational improvements that increase enterprise value, and preparing companies for exit through targeted remediation and quality system maturation.
What Good Due Diligence Looks Like
In one recent engagement, QxP supported the acquisition of a clinical-stage biotech by a mid-size pharmaceutical company. A cross-functional QxP team conducted a comprehensive technical review and uncovered major gaps in the target's stability data program - gaps that hadn't appeared in the initial financial and legal review. The team also identified a significant misalignment between the target's development-stage quality practices and the standards required for commercial manufacturing.
Those findings did three things. They enabled the acquirer to negotiate a materially lower valuation. They produced a detailed 18-month remediation roadmap that became the post-close integration plan. And they prevented what could have been a costly delay in IND advancement - a delay that, undiscovered, would have compounded well beyond the deal price.
That's what technical due diligence is for.
Starting the Conversation
Due diligence is not a box to check. In pharmaceutical transactions, it's a risk management discipline - and when done well, it's a value creation tool. The risks that QxP uncovers don't just protect acquirers from bad deals. They surface negotiating leverage, integration priorities, and operational roadmaps that drive better outcomes on the other side of close.
If you're evaluating an acquisition, preparing for one, selecting a manufacturing partner, or advising on a life sciences investment, QxP is ready to be your technical partner in that process.
Contact QxP to discuss your due diligence needs →
Quality Executive Partners (QxP) is a global consulting and training firm serving the pharmaceutical, biotech, and life sciences industries. Our experts bring hands-on technical and operational experience across quality, manufacturing, regulatory affairs, and advanced modalities to every engagement.
